Martine Rothblatt Sells 2,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 2,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $507.07, for a total transaction of $1,014,140.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $65,919.10. This trade represents a 93.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Up 2.0%

NASDAQ UTHR traded up $10.13 during trading hours on Friday, reaching $517.13. 1,683,681 shares of the company were exchanged, compared to its average volume of 583,124. The stock has a market capitalization of $22.27 billion, a P/E ratio of 19.60, a P/E/G ratio of 5.07 and a beta of 0.86. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $518.61. The business’s 50 day simple moving average is $462.08 and its 200-day simple moving average is $379.23.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter last year, the business posted $6.39 EPS. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of the company. AQR Capital Management LLC increased its holdings in United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the period. Invesco Ltd. increased its holdings in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics in the third quarter worth $317,617,000. Assetmark Inc. boosted its stake in United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after buying an additional 197,384 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in United Therapeutics by 22.5% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company’s stock worth $147,278,000 after buying an additional 87,664 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on UTHR. HC Wainwright increased their price target on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Cantor Fitzgerald boosted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a report on Monday, December 8th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.